Genetic vaccination with Flt3-L and GM-CSF as adjuvants: Enhancement of cellular and humoral immune responses that results in protective immunity in a murine model of hepatitis C virus infection

Figure 4 Tumor model to assess CTL activity generated in vivo after genetic vaccination. Mice were immunized three times with a total of 100 μg of plasmid DNA. Each vaccination group (n = 8) was challenged with 2 × 10⁶ syngenic mouse myeloma cells stably expressing HCV-NS5 protein in the right flank. Mice developed notable tumors around d 8-10. (A) Tumor size in different immunization groups. Note that mice had to be sacrificed at maximum tumor diameter size of 2 cm. Sacrificed mice were then taken out from the measurement. (B) Mouse survival after genetic vaccination in each group. Three mice were long-term survivor and never developed significant tumor burden.